NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1
Company Announcements

NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1

NeuroBo Pharmaceuticals ( (NRBO) ) just unveiled an update.

NeuroBo Pharmaceuticals, Inc. has announced promising results from Part 1 of the Phase 1 clinical trial for its obesity treatment, DA-1726, which showcases favorable safety, tolerability, and dose-linear pharmacokinetics. The trial, involving 45 obese yet otherwise healthy participants, reported no serious adverse events, setting a positive stage for the future phases of the research. Eagerly anticipated is the top-line data from the ongoing multiple ascending dose study, as well as an early proof of concept from the planned Part 3 of the trial, which collectively aim to position DA-1726 as a potentially superior obesity treatment option.

Learn more about NRBO stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNeuroBo Pharmaceuticals Completes Phase 2a Trial for MASH Drug
TheFlyNeuroBo Pharmaceuticals completes last patient visit in Phase 2a DA-1241 trial
TipRanks Auto-Generated NewsdeskNeuroBo Pharmaceuticals Unveils Updated Corporate Presentation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App